Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2004-10-13
pubmed:abstractText
The purpose of this phase II trial was to compare the efficacy, safety and pharmacokinetics of four irinotecan schedules for the treatment of metastatic colorectal cancer. In total, 174 5-fluorouracil pretreated patients were randomised to: arm A (n=41), 350 mg m(-2) irinotecan as a 90-min i.v. infusion q3 weeks; arm B (n=38), 125 mg m(-2) irinotecan as a 90-min i.v. infusion weekly x 4 weeks q6 weeks; arm C (n=46), 250 mg m(-2) irinotecan as a 90-min i.v. infusion q2 weeks; or arm D (n=49), 10 mg m(-2) day(-1) irinotecan as a 14-day continuous infusion q3 weeks. No significant differences in efficacy across the four arms were observed, although a shorter time to treatment failure was noted for arm D (1.7 months; P=0.02). Overall response rates were in the range 5-11%. Secondary end points included median survival (6.4-9.4 months), and time to progression (2.7-3.8 months) and treatment failure (1.7-3.2 months). Similarly, there were no significant differences in the incidence of grade 3-4 toxicities, although the toxicity profile between arms A, B, and C and D did differ. Generally, significantly less haematologic toxicity, alopecia and cholinergic syndrome were observed in arm D; however, there was a trend for increased gastrointestinal toxicity. Irinotecan is an effective and safe second-line treatment for colorectal cancer. The schedules examined yielded equivalent results, indicating that there is no advantage of the prolonged vs short infusion schedules.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-10408839, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-10561231, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-10570064, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-10653882, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-10744089, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-12610178, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-1331485, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2230878, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2297233, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2545341, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2548710, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2553253, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-2997227, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-3931953, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-7634381, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-7786822, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-8210255, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-8487053, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-8648367, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-8831730, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-8996150, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9193346, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9256135, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9272733, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9321519, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9488652, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9516936, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9807987, http://linkedlifedata.com/resource/pubmed/commentcorrection/15381932-9918204
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:day
18
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1434-41
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
pubmed:affiliation
Antoni van Leeuwenhoek Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands.
More...